Mohan, Sanjay R
Vanderbilt Health
4 papers on CoChatORCID 0000-0002-6715-6697
Most cited papers
- Verified
Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Gotlib, J., Gerds, A. T., Bose, P., Castells, M. C., Deininger, M. W., Gojo, I., Gundabolu, K., Hobbs, G., Jamieson, C., McMahon, B., et al. (2018) · Journal of the National Comprehensive Cancer Network
Mast cells and histamineGastrointestinal Tumor Research and Treatment
Cited by 106
- Verified
BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis
Verstovsek, S., Al-Ali, H. K., Mascarenhas, J., Perkins, A., Vannucchi, A. M., Mohan, S. R., Scott, B. L., Woszczyk, D., Koschmieder, S., García-Delgado, R., et al. (2022) · Future Oncology
Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research
Cited by 41
- Verified
Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis
Mascarenhas, J. O., Popov, V. M., Mohan, S., Özkurt, Z. N., Kiladjian, J.-J., Al-Ali, H. K., Perkins, A., Huang, Z., Qamoos, H., McGreivy, J., et al. (2024) · Blood
Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research
Cited by 17
- Verified
Disease-modifying activity of navtemadlin correlates with clinical responses in a randomized, multicenter, global phase 3 study (BOREAS) in JAK-inhibitor relapsed/refractory myelofibrosis
Mascarenhas, J. O., Bose, P., Hou, H.-A., Homenda, W., Ross, D., Mohan, S. R., Kiladjian, J.-J., Al-Ali, H. K., Perkins, A., Khalina, Y., et al. (2024) · Blood
Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research
Cited by 8
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free